CD274 and lung cancer: The development of anti‐PD‐(L)1 agents has revolutionized the treatment paradigms of non‐small cell lung cancer (NSCLC) with long lasting therapy responses and clinically meaningful overall survival benefit.4, 5, 6, 7, 8, 15